Composition for predicting chemotherapy resistance of ovarian cancer and use thereof

A method of treating a patient with resistance to chemotherapy in ovarian cancer, comprising:

• (a) measuring expression level of exosome-derived LHX6 in a non-invasive biological sample of blood or serum isolated from an ovarian cancer patient;
• (b) determining that the patient with ovarian cancer is resistant to chemotherapy when expression level of LHX6 in the sample of the (a) is lower than expression level of normal control compared to the expression level of the normal control;
• and
• (c) treating the patient with at least one selected from the group consisting of LHX6, an LHX6 activator and an LHX6 expression promoter, and chemotherapy.

A method of screening a sensitizer for chemotherapy in treatment of ovarian cancer, comprising:

• (a) measuring expression level of exosome-derived miR-214-3p or LHX6 obtained from blood or serum isolated from a patient with ovarian cancer;
• (b) measuring expression level of exosome-derived miR-214-3p or LHX6 after treating a candidate material with blood or serum isolated from a patient with ovarian cancer;
• and
• (c) determining that the candidate material is a sensitizer for chemotherapy when expression level of exosome-derived miR-214-3p in the (b) is lower than expression level of exosome-derived miR-214-3p in the (a), or expression level of LHX6 in the (b) is higher than expression level of LHX6 in the (a).